EphA3 biology and cancer

References

• Adams RH, Eichmann A. 2010. Axon guidancemolecules in vascular patterning. Cold Spring Harb Perspect Biol 2:a001875
   PubMed Web of Science ®Google Scholar
• Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, Risau W, Klein R. 1999. Roles of ephrinB ligands and EphB receptors in cardiovascular development: Demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 13:295–306
   PubMed Web of Science ®Google Scholar
• Aoki M, Yamashita T, Tohyama M. 2004. EphA receptors direct the differentiation of mammalian neural precursor cells through a mitogen-activated protein kinase-dependent pathway. J Biol Chem 279:32643–32650
   Google Scholar
• Arruga F, Messa F, Carturan S, Pradatto M, Maff C, Pautasso M, Panuzzo C, et al. 2009. EphA3 is abnormally expressed in chronic myeloproliferative disorders and could represent a new molecular target. Proc Am Assoc Cancer Res AACR 2009:Abstract nr 2866
   Google Scholar
• Ashton JM, Balys M, Neering SJ, Hassane DC, Cowley GR, David EM, Peter GE, et al. 2012. Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells. Cell Stem Cell 11:359–372
   Google Scholar
• Atapattu L, Lackmann M, Janes PW. 2014. The role of proteases in regulating Eph/ephrin signalling. Cell Adh Migr, in press
   Google Scholar
• Atapattu L, Saha N, Llerena C, Vail ME, Scott AM, Nikolov DB, Lackmann M, Janes PW. 2012. Antibodies binding the ADAM10 substrate recognition domain inhibit Eph function. J Cell Sci 125:6084–6093
   Google Scholar
• Balakrishnan A, Bleeker FE, Lamba S, Rodolfo M, Daniotti M, Scarpa A, van Tilborg AA, et al. 2007. Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res 67:3545–3550
   PubMed Web of Science ®Google Scholar
• Bao B, Azmi AS, Ali S, Ahmad A, Li Y, Banerjee S, Kong D, Sarkar FH. 2012. The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta 1826:272–296
   PubMed Web of Science ®Google Scholar
• Barcellos-de-Souza P, Gori V, Bambi F, Chiarugi P. 2013. Tumor microenvironment: Bone marrow-mesenchymal stem cells as key players. Biochim Biophys Acta 1836:321–335
   PubMed Web of Science ®Google Scholar
• Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, Markowitz S, et al. 2003. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300:949
   PubMed Web of Science ®Google Scholar
• Bea S, Valdes-Mas R, Navarro A, Salaverria I, Martin-Garcia D, Jares P, Gine E, et al. 2013. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A 110:18250–18255
   PubMed Web of Science ®Google Scholar
• Bianco P, Robey PG, Simmons PJ. 2008. Mesenchymal stem cells: Revisiting history, concepts, and assays. Cell Stem Cell 2:313–319
   PubMed Web of Science ®Google Scholar
• Binda E, Visioli A, Giani F, Lamorte G, Copetti M, Pitter KL, Huse JT, et al. 2012. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell 22:765–780
   PubMed Web of Science ®Google Scholar
• Birgbauer E, Cowan CA, Sretavan DW, Henkemeyer M. 2000. Kinase independent function of EphB receptors in retinal axon pathfinding to the optic disc from dorsal but not ventral retina. Development 127:1231–1241
   PubMedGoogle Scholar
• Bonifaci N, Górski B, Masojć B, Wokołorczyk D, Jakubowska A, Dębniak T, Berenguer A, et al. 2010. Exploring the link between germline and somatic genetic alterations in breast carcinogenesis. PLoS ONE 5:e14078
   Google Scholar
• Bosco MC, Pierobon D, Blengio F, Raggi F, Vanni C, Gattorno M, Eva A, et al. 2011. Hypoxia modulates the gene expression profile of immunoregulatory receptors in human mature dendritic cells: Identification of TREM-1 as a novel hypoxic marker in vitro and in vivo. Blood 117:2625–2639
   PubMed Web of Science ®Google Scholar
• Boyd AW, Bartlett PF, Lackmann M. 2014. Therapeutic targeting of EPH receptors and their ligands. Nat Rev Drug Discov 13:39–62
   Google Scholar
• Boyd AW, Ward LD, Wicks IP, Simpson RJ, Salvaris E, Wilks A, Welch K, et al. 1992. Isolation and characterization of a novel receptor-type protein tyrosine kinase (hek) from a human pre-B cell line. J Biol Chem 267: 3262–3267
   PubMedGoogle Scholar
• Brantley-Sieders DM, Caughron J, Hicks D, Pozzi A, Ruiz JC, Chen J. 2004. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J Cell Sci 117:2037–2049
   PubMed Web of Science ®Google Scholar
• Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, Coffman K, et al. 2008. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 118:64–78
   PubMed Web of Science ®Google Scholar
• Brennaman LH, Moss ML, Maness PF. 2014. EphrinA/EphA-induced ectodomain shedding of neural cell adhesion molecule regulates growth cone repulsion through ADAM10 metalloprotease. J Neurochem 128:267–279
   Google Scholar
• Brown A, Yates PA, Burrola P, Ortuno D, Vaidya A, Jessell TM, Pfaff SL, O'Leary DD, Lemke G. 2000. Topographic mapping from the retina to the midbrain is controlled by relative but not absolute levels of EphA receptor signaling. Cell 102:77–88
   PubMed Web of Science ®Google Scholar
• Bush JO, Soriano P. 2010. Ephrin-B1 forward signaling regulates craniofacial morphogenesis by controlling cell proliferation across Eph–ephrin boundaries. Genes Dev 24:2068–2080
   PubMedGoogle Scholar
• Caivano A, La Rocca F, Laurenzana I, Favole A, Airoldi I, Di Carlo E, Gaidano V, et al. 2013. EphA3 as a molecular target in multiple myeloma: Opportunity for a novel therapeutic approach with a specific monoclonal antibody. Blood (ASH Annual Meeting Abstracts) 122:3211
   Google Scholar
• Carter N, Nakamoto T, Hirai H, Hunter T. 2002. EphrinA1-induced cytoskeletal re-organization requires FAK and p130(cas). Nat Cell Biol 4:565–573
   PubMedGoogle Scholar
• Casey J, Magalhaes T, Conroy J, Regan R, Shah N, Anney R, Shields D, et al. 2012. A novel approach of homozygous haplotype sharing identifies candidate genes in autism spectrum disorder. Hum Genet 131:565–579
   PubMed Web of Science ®Google Scholar
• Castellani CA, Awamleh Z, Melka MG, O'Reilly RL, Singh SM. 2014. Copy number variation distribution in six monozygotic twin pairs discordant for schizophrenia. Twin Res Hum Genet 17:108–120
   Google Scholar
• Chang L-C, Jamain S, Lin C-W, Rujescu D, Tseng GC, Sibille E. 2014. A conserved BDNF, glutamate- and GABA-enriched gene module related to human depression identified by coexpression meta-analysis and DNA variant genome-wide association studies. PLoS ONE 9:e90980
   PubMed Web of Science ®Google Scholar
• Charmsaz S, Miller KJ, Day BW, El-Ajeh F, Yarranton GT, Bebbington CR, Scott AM, et al. 2013. EphA3 as a target for monoclonal antibody therapy for acute leukemia. Blood (ASH Annual Meeting Abstracts) 122:5013
   Google Scholar
• Chen J, Guo L, Peiffer DA, Zhou L, Chan OTM, Bibikova M, Wickham-Garcia E, et al. 2008. Genomic profiling of 766 cancer-related genes in archived esophageal normal and carcinoma tissues. Int J Cancer 122:2249–2254
   Google Scholar
• Chen J, Song W, Amato K. 2014. Eph receptor tyrosine kinases in cancer stem cells. Cytokine Growth Factor Rev (in press). doi: http://dx.doi.org/10.1016/j.cytogfr.2014.05.001
   Google Scholar
• Cheng HJ, Nakamoto M, Bergemann AD, Flanagan JG. 1995. Complementary gradients in expression and binding of ELF-1 and Mek4 in development of the topographic retinotectal projection map. Cell 82:371–381
   PubMed Web of Science ®Google Scholar
• Chiappalupi S, Riuzzi F, Fulle S, Donato R, Sorci G. 2014. Defective RAGE activity in embryonal rhabdomyosarcoma cells results in high PAX7 levels that sustain migration and invasiveness. Carcinogenesis 35:2382–2392
   PubMed Web of Science ®Google Scholar
• Chiari R, Hames G, Stroobant V, Texier C, Maillere B, Boon T, Coulie PG. 2000. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res 60:4855–4863
   PubMed Web of Science ®Google Scholar
• Choi Y, Syeda F, Walker JR, Finerty Jr PJ, Cuerrier D, Wojciechowski A, Liu Q, et al. 2009. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett 19:4467–4470
   PubMedGoogle Scholar
• Cilloni D, Arruga F, Carturan S, Messa F, Pradotto M, Defilippi I, Pautasso M, et al. 2008. EphA3 kinase is constitutively activated in chronic myeloid leukaemia during progression to accelerated and blast crisis and it could represent a new molecular target. ASH Annual Meeting Abstract, Paper 9247
   Google Scholar
• Clifford N, Smith LM, Powell J, Gattenlohner S, Marx A, O'Connor R. 2008. The EphA3 receptor is expressed in a subset of rhabdomyosarcoma cell lines and suppresses cell adhesion and migration. J Cell Biochem 105:1250–1259
   Google Scholar
• Connor RJ, Menzel P, Pasquale EB. 1998. Expression and tyrosine phosphorylation of Eph receptors suggest multiple mechanisms in patterning of the visual system. Dev Biol 193:21–35
   PubMed Web of Science ®Google Scholar
• Cooke JE, Kemp HA, Moens CB. 2005. EphA4 is required for cell adhesion and rhombomere-boundary formation in the zebrafish. Curr Biol 15:536–542
   PubMedGoogle Scholar
• Corbo V, Ritelli R, Barbi S, Funel N, Campani D, Bardelli A, Scarpa A. 2010. Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas. PLoS ONE 5:e12653
   PubMed Web of Science ®Google Scholar
• Cortina C, Palomo-Ponce S, Iglesias M, Fernandez-Masip JL, Vivancos A, Whissell G, Huma M, et al. 2007. EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat Genet 39:1376–1383
   PubMed Web of Science ®Google Scholar
• Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G, Teague J, et al. 2005. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65:7591–7595
   PubMed Web of Science ®Google Scholar
• Davis S, Gale NW, Aldrich TH, Maisonpierre PC, Lhotak V, Pawson T, Goldfarb M, Yancopoulos GD. 1994. Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science 266:816–819
   PubMed Web of Science ®Google Scholar
• Davis TL, Walker JR, Loppnau P, Butler-Cole C, Allali-Hassani A, Dhe-Paganon S. 2008. Autoregulation by the juxtamembrane region of the human ephrin receptor tyrosine kinase A3 (EphA3). Structure 16:873–884
   PubMedGoogle Scholar
• Day B, To C, Himanen JP, Smith FM, Nikolov DB, Boyd AW, Lackmann M. 2005. Three distinct molecular surfaces in ephrin-A5 are essential for a functional interaction with EphA3. J Biol Chem 280:26526–26532
   PubMedGoogle Scholar
• Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR, et al. 2013. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell 23:238–248
   PubMed Web of Science ®Google Scholar
• Day BW, Stringer BW, Boyd AW. 2014. Eph receptors as therapeutic targets in glioblastoma. Br J Cancer 111:1255–1261
   PubMed Web of Science ®Google Scholar
• Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, et al. 2008. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069–1075
   PubMed Web of Science ®Google Scholar
• Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, et al. 2012. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481:506–510
   PubMed Web of Science ®Google Scholar
• Dobrzanski P, Hunter K, Jones-Bolin S, Chang H, Robinson C, Pritchard S, Zhao H, Ruggeri B. 2004. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res 64: 910–919
   PubMed Web of Science ®Google Scholar
• Dottori M, Down M, Huttmann A, Fitzpatrick DR, Boyd AW. 1999. Cloning and characterization of EphA3 (Hek) gene promoter: DNA methylation regulates expression in hematopoietic tumor cells. Blood 94:2477–2486
   PubMed Web of Science ®Google Scholar
• Durbin L, Brennan C, Shiomi K, Cooke J, Barrios A, Shanmugalingam S, Guthrie B, et al. 1998. Eph signaling is required for segmentation and differentiation of the somites. Genes Dev 12:3096–3109
   PubMedGoogle Scholar
• Easty DJ, Bennett DC. 2000. Protein tyrosine kinases in malignant melanoma. Melanoma Res 10:401–411
   PubMedGoogle Scholar
• Easty DJ, Herlyn M, Bennett DC. 1995. Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int J Cancer 60:129–136
   Google Scholar
• Elowe S, Holland SJ, Kulkarni S, Pawson T. 2001. Downregulation of the Ras-mitogen-activated protein kinase pathway by the EphB2 receptor tyrosine kinase is required for ephrin-induced neurite retraction. Mol Cell Biol 21:7429–7441
   PubMed Web of Science ®Google Scholar
• Fawcett JP, Georgiou J, Ruston J, Bladt F, Sherman A, Warner N, Saab BJ, et al. 2007. Nck adaptor proteins control the organization of neuronal circuits important for walking. Proc Natl Acad Sci USA 104:20973–20978
   PubMed Web of Science ®Google Scholar
• Finger C, Escher C, Schneider D. 2009. The single transmembrane domains of human receptor tyrosine kinases encode self-interactions. Sci Signal 2:ra56
   Google Scholar
• Foo SS, Turner CJ, Adams S, Compagni A, Aubyn D, Kogata N, Lindblom P, et al. 2006. Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. Cell 124:161–173
   PubMed Web of Science ®Google Scholar
• Fournier MV, Martin KJ, Kenny PA, Xhaja K, Bosch I, Yaswen P, Bissell MJ. 2006. Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. Cancer Res 66:7095–7102
   Google Scholar
• Fox BP, Tabone CJ, Kandpal RP. 2006. Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines. Biochem Biophys Res Commun 342:1263–1272
   Google Scholar
• Frieden LA, Townsend TA, Vaught DB, Delaughter DM, Hwang Y, Barnett JV, Chen J. 2010. Regulation of heart valve morphogenesis by Eph receptor ligand, ephrin-A1. Dev Dynam 239:3226–3234
   PubMedGoogle Scholar
• Gallarda BW, Bonanomi D, Muller D, Brown A, Alaynick WA, Andrews SE, Lemke G, et al. 2008. Segregation of axial motor and sensory pathways via heterotypic trans-axonal signaling. Science 320:233–236
   Google Scholar
• Gerety SS, Anderson DJ. 2002. Cardiovascular ephrinB2 function is essential for embryonic angiogenesis. Development 129:1397–1410
   PubMed Web of Science ®Google Scholar
• Gerety SS, Wang HU, Chen ZF, Anderson DJ. 1999. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 4:403–414
   PubMed Web of Science ®Google Scholar
• Greene AC, Lord SJ, Tian A, Rhodes C, Kai H, Groves JT. 2014. Spatial organization of EphA2 at the cell-cell interface modulates trans-endocytosis of EphrinA1. Biophys J 106:2196–2205
   Google Scholar
• Guan M, Liu L, Zhao X, Wu Q, Yu B, Shao Y, Yang H, et al. 2011. Copy number variations of EphA3 are associated with multiple types of hematologic malignancies. Clin Lymphoma Myeloma Leuk 11:50–53
   PubMedGoogle Scholar
• Harrison JS, Rameshwar P, Chang V, Bandari P. 2002. Oxygen saturation in the bone marrow of healthy volunteers. Blood 99:394
   PubMed Web of Science ®Google Scholar
• Hattori M, Osterfield M, Flanagan JG. 2000. Regulated cleavage of a contact-mediated axon repellent. Science 289:1360–1365
   PubMed Web of Science ®Google Scholar
• Herath NI, Spanevello MD, Doecke JD, Smith FM, Pouponnot C, Boyd AW. 2012. Complex expression patterns of Eph receptor tyrosine kinases and their ephrin ligands in colorectal carcinogenesis. Eur J Cancer 48:753–762
   Google Scholar
• Hess AR, Margaryan NV, Seftor EA, Hendrix MJ. 2007. Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: Role of the Eph receptors. Dev Dynam 236:3283–3296
   Google Scholar
• Himanen JP, Chumley MJ, Lackmann M, Li C, Barton WA, Jeffrey PD, Vearing C, et al. 2004. Repelling class discrimination: Ephrin-A5 binds to and activates EphB2 receptor signaling. Nat Neurosci 7:501–509
   PubMed Web of Science ®Google Scholar
• Himanen JP, Rajashankar KR, Lackmann M, Cowan CA, Henkemeyer M, Nikolov DB. 2001. Crystal structure of an Eph receptor-ephrin complex. Nature 414:933–938
   PubMed Web of Science ®Google Scholar
• Himanen JP, Yermekbayeva L, Janes PW, Walker JR, Xu K, Atapattu L, Rajashankar KR, et al. 2010. Architecture of Eph receptor clusters. Proc Natl Acad Sci USA 107:10860–10865
   PubMedGoogle Scholar
• Hinoue T, Weisenberger DJ, Pan F, Campan M, Kim M, Young J, Whitehall VL, et al. 2009. Analysis of the association between CIMP and BRAFV600E in colorectal cancer by DNA Methylation Profiling. PLoS ONE 4:e8357
   PubMedGoogle Scholar
• Holland SJ, Gale NW, Gish GD, Roth RA, Songyang Z, Cantley LC, Henkemeyer M, et al. 1997. Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells. EMBO J 16:3877–3888
   PubMed Web of Science ®Google Scholar
• Holmberg J, Clarke DL, Frisen J. 2000. Regulation of repulsion versus adhesion by different splice forms of an Eph receptor. Nature 408:203–206
   PubMed Web of Science ®Google Scholar
• Hou F, Yuan W, Huang J, Qian L, Chen Z, Ge J, Wu S, et al. 2012. Overexpression of EphA2 correlates with epithelial-mesenchymal transition-related proteins in gastric cancer and their prognostic importance for postoperative patients. Medl Oncol 29:2691–2700
   Google Scholar
• Hu T, Shi G, Larose L, Rivera GM, Mayer BJ, Zhou R. 2009. Regulation of process retraction and cell migration by EphA3 is mediated by the adaptor protein Nck1. Biochemistry 48:6369–6378
   PubMedGoogle Scholar
• Huang J, Xiao D, Li G, Ma J, Chen P, Yuan W, Hou F, et al. 2014. EphA2 promotes epithelial-mesenchymal transition through the Wnt/[beta]-catenin pathway in gastric cancer cells. Oncogene 33:2737–2747
   Google Scholar
• Huang X, Wu D, Jin H, Stupack D, Wang JY. 2008. Induction of cell retraction by the combined actions of Abl-CrkII and Rho-ROCK1 signaling. J Cell Biol 183:711–723
   Google Scholar
• Iacobucci I, Ottaviani E, Guadagnuolo V, Paolini S, Cilloni D, Messa F, Candoni A, et al. 2010. High-resolution molecular allelokaryotyping identifies novel genomic alterations in acute promyelocytic leukemia (APL). Proc Am Assoc Cancer Res 70:Abstract nr 656
   Google Scholar
• Iwamasa H, Ohta K, Yamada T, Ushijima K, Terasaki H, Tanaka H. 1999. Expression of Eph receptor tyrosine kinases and their ligands in chick embryonic motor neurons and hindlimb muscles. Dev Growth Differ 41:685–698
   PubMedGoogle Scholar
• Janes PW, Adikari S, Lackmann M. 2008. Eph/Ephrin signalling and function in oncogenesis: Lessons from embryonic development. Curr Cancer Drug Targets 8:473–479
   PubMed Web of Science ®Google Scholar
• Janes PW, Griesshaber B, Atapattu L, Nievergall E, Hii LL, Mensinga A, Chheang C, et al. 2011. Eph receptor function is modulated by heterooligomerization of A and B type Eph receptors. J Cell Biol 195:1033–1045
   Google Scholar
• Janes PW, Saha N, Barton WA, Kolev MV, Wimmer-Kleikamp SH, Nievergall E, Blobel CP, et al. 2005. Adam meets Eph: An ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 123:291–304
   PubMed Web of Science ®Google Scholar
• Janes PW, Wimmer-Kleikamp SH, Frangakis AS, Treble K, Griesshaber B, Sabet O, Grabenbauer M, et al. 2009. Cytoplasmic relaxation of active Eph controls ephrin shedding by ADAM10. PLoS Biol 7:e1000215
   Google Scholar
• Jorgensen C, Sherman A, Chen GI, Pasculescu A, Poliakov A, Hsiung M, Larsen B, et al. 2009. Cell-specific information processing in segregating populations of eph receptor ephrin-expressing cells. Science 326:1502–1509
   PubMed Web of Science ®Google Scholar
• Julien SG, Dubé, N., Hardy S, Tremblay ML. 2011. Inside the human cancer tyrosine phosphatome. Nat Rev Cancer 11:35–49
   PubMed Web of Science ®Google Scholar
• Kahn J, Walcheck B, Migaki GI, Jutila MA, Kishimoto TK. 1998. Calmodulin regulates L-selectin adhesion molecule expression and function through a protease-dependent mechanism. Cell 92:809–818
   PubMedGoogle Scholar
• Kalluri R, Zeisberg M. 2006. Fibroblasts in cancer. Nat Rev Cancer 6:392–401
   PubMed Web of Science ®Google Scholar
• Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, et al. 2010. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466:7308
   Google Scholar
• Kawakami Y, Uchiyama Y, Rodriguez Esteban C, Inenaga T, Koyano-Nakagawa N, Kawakami H, Marti M, et al. 2009. Sall genes regulate region-specific morphogenesis in the mouse limb by modulating Hox activities. Development 136:585–594
   PubMed Web of Science ®Google Scholar
• Keane N, Freeman C, Swords R, Giles FJ. 2012. EPHA3 as a novel therapeutic target in the hematological malignancies. Expert Rev Hematol 5:325–340
   PubMed Web of Science ®Google Scholar
• Kilpatrick TJ, Brown A, Lai C, Gassmann M, Goulding M, Lemke G. 1996. Expression of the Tyro4/Mek4/Cek4 gene specifically marks a subset of embryonic motor neurons and their muscle targets. Mol Cell Neurosci 7:62–74
   PubMedGoogle Scholar
• Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, Sara H, Pisto T, et al. 2008. Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. Genome Biol 9:R139
   PubMed Web of Science ®Google Scholar
• Kullander K, Mather NK, Diella F, Dottori M, Boyd AW, Klein R. 2001. Kinase-dependent and kinase-independent functions of EphA4 receptors in major axon tract formation in vivo. Neuron 29:73–84
   PubMed Web of Science ®Google Scholar
• Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, Scehnet J, et al. 2006. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol 169:279–293
   PubMed Web of Science ®Google Scholar
• Lackmann M, Bucci T, Mann RJ, Kravets LA, Viney E, Smith F, Moritz RL, et al. 1996. Purification of a ligand for the EPH-like receptor HEK using a biosensor-based affinity detection approach. Proc Natl Acad Sci USA 93:2523–2527
   PubMedGoogle Scholar
• Lackmann M, Mann RJ, Kravets L, Smith FM, Bucci TA, Maxwell KF, Howlett GJ, et al. 1997. Ligand for EPH-related kinase (LERK) 7 is the preferred high affinity ligand for the HEK receptor. J Biol Chem 272:16521–16530
   PubMedGoogle Scholar
• Lackmann M, Oates AC, Dottori M, Smith FM, Do C, Power M, Kravets L, Boyd AW. 1998. Distinct subdomains of the EphA3 receptor mediate ligand binding and receptor dimerization. J Biol Chem 273:20228–20237
   PubMedGoogle Scholar
• Lawrenson ID, Wimmer-Kleikamp SH, Lock P, Schoenwaelder SM, Down M, Boyd AW, Alewood PF, Lackmann M. 2002. Ephrin-A5 induces rounding, blebbing and de-adhesion of EphA3- expressing 293T and melanoma cells by CrkII and Rho-mediated signalling. J Cell Sci 115:1059–1072
   PubMed Web of Science ®Google Scholar
• Leone M, Cellitti J, Pellecchia M. 2008. NMR studies of a heterotypic Sam-Sam domain association: The interaction between the lipid phosphatase Ship2 and the EphA2 receptor. Biochemistry 47:12721–12728
   PubMedGoogle Scholar
• Li W, Fan J, Woodley DT. 2001. Nck/Dock: An adapter between cell surface receptors and the actin cytoskeleton. Oncogene 20:6403–6417
   PubMed Web of Science ®Google Scholar
• Lin CS, Lue TF. 2013. Defining vascular stem cells. Stem Cells Dev 22:1018–1026
   PubMed Web of Science ®Google Scholar
• Lisabeth EM, Fernandez C, Pasquale EB. 2012. Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms. Biochemistry 51:1464–1475
   PubMedGoogle Scholar
• Lu C, Yang Z, Zhou L, Huang Z, Zhang H, Li J, Tao K, Xie B. 2013. High levels of EphA3 expression are associated with high invasive capacity and poor overall survival in hepatocellular carcinoma. Oncol Reports 30:2179–2186
   Google Scholar
• Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, et al. 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715
   PubMed Web of Science ®Google Scholar
• Marie-Egyptienne DT, Lohse I, Hill RP. 2013. Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett 341:63–72
   PubMed Web of Science ®Google Scholar
• Martin-Rendon E, Hale SJ, Ryan D, Baban D, Forde SP, Roubelakis M, Sweeney D, et al. 2007. Transcriptional profiling of human cord blood CD133+ and cultured bone marrow mesenchymal stem cells in response to hypoxia. Stem Cells 25:1003–1012
   PubMed Web of Science ®Google Scholar
• Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R, Olsen BR. 2010. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med 16:1400–1406
   PubMed Web of Science ®Google Scholar
• Mosch B, Pietzsch D, Pietzsch J. 2012. Irradiation affects cellular properties and Eph receptor expression in human melanoma cells. Cell Adh Migr 6:113–125
   PubMed Web of Science ®Google Scholar
• Nievergall E, Janes PW, Stegmayer C, Vail ME, Haj FG, Teng SW, Neel BG, et al. 2010. PTP1B regulates Eph receptor function and trafficking. J Cell Biol 191:1189–1203
   PubMedGoogle Scholar
• Nievergall E, Lackmann M, Janes PW. 2012. Eph-dependent cell-cell adhesion and segregation in development and cancer. Cell Mol Life Sci 69:1813–1842
   Google Scholar
• Noren NK, Foos G, Hauser CA, Pasquale EB. 2006. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol 8:815–825
   PubMed Web of Science ®Google Scholar
• Noren NK, Lu M, Freeman AL, Koolpe M, Pasquale EB. 2004. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci USA 101:5583–5588
   PubMed Web of Science ®Google Scholar
• Oates AC, Lackmann M, Power MA, Brennan C, Down LM, Do C, Evans B, et al. 1999. An early developmental role for eph-ephrin interaction during vertebrate gastrulation. Mech Dev 83:77–94
   PubMedGoogle Scholar
• Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. 2000. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19:6043–6052
   PubMed Web of Science ®Google Scholar
• Palath V, Vekhande R, Lee A, Williams J, Zhang L, List AF, Boyd A, et al. 2009. A recombinant human antibody to EphA3 with pro-apoptotic and and enhanced ADCC activity shows selective cytotoxicity against myeloid leukemia cells and CD123-positive leukemic stem cells. Blood (ASH Annual Meeting Abstracts) 114:1728
   Google Scholar
• Park IH, Kim KH, Choi HK, Shim JS, Whang SY, Hahn SJ, Kwon OJ, Oh IH. 2013. Constitutive stabilization of hypoxia-inducible factor alpha selectively promotes the self-renewal of mesenchymal progenitors and maintains mesenchymal stromal cells in an undifferentiated state. Exp Mol Med 45:e44
   Google Scholar
• Pasquale EB. 2008. Eph-ephrin bidirectional signaling in physiology and disease. Cell 133:38–52
   PubMed Web of Science ®Google Scholar
• Pasquale EB. 2010. Eph receptors and ephrins in cancer: Bidirectional signalling and beyond. Nat Rev Cancer 10:165–180
   PubMed Web of Science ®Google Scholar
• Poliakov A, Cotrina ML, Pasini A, Wilkinson DG. 2008. Regulation of EphB2 activation and cell repulsion by feedback control of the MAPK pathway. J Cell Biol 183:933–947
   Google Scholar
• Polyak K, Weinberg RA. 2009. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 9:265–273
   PubMed Web of Science ®Google Scholar
• Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N, Escaramis G, et al. 2011. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475:101–105
   PubMed Web of Science ®Google Scholar
• Qin H, Noberini R, Huan X, Shi J, Pasquale EB, Song J. 2009. Structural characterization of the EphA4-Ephrin-B2 complex reveals new features enabling Eph-ephrin binding promiscuity. J Biol Chem 285:644–654
   Google Scholar
• Reber M, Burrola P, Lemke G. 2004. A relative signalling model for the formation of a topographic neural map. Nature 431:847–853
   PubMed Web of Science ®Google Scholar
• Reiss K, Saftig P. 2009. The “A Disintegrin And Metalloprotease” (ADAM) family of sheddases: Physiological and cellular functions. Semin Cell Dev Biol 20:126–137
   PubMed Web of Science ®Google Scholar
• Ross JS, Wang K, Elkadi OR, Tarasen A, Foulke L, Sheehan CE, Otto GA, et al. 2014. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. J Clin Pathol 67:772–776
   Google Scholar
• Ruiz JC, Robertson EJ. 1994. The expression of the receptor-protein tyrosine kinase gene, eck, is highly restricted during early mouse development. Mech Dev 46:87–100
   PubMedGoogle Scholar
• Salaita K, Nair PM, Petit RS, Neve RM, Das D, Gray JW, Groves JT. 2010. Restriction of receptor movement alters cellular response: Physical force sensing by EphA2. Science 327:1380–1385
   PubMed Web of Science ®Google Scholar
• Seiradake E, Harlos K, Sutton G, Aricescu AR, Jones EY. 2010. An extracellular steric seeding mechanism for Eph-ephrin signaling platform assembly. Nat Struct Mol Biol 17:398–402
   PubMedGoogle Scholar
• Shintani T, Ihara M, Sakuta H, Takahashi H, Watakabe I, Noda M. 2006. Eph receptors are negatively controlled by protein tyrosine phosphatase receptor type O. Nat Neurosci 9:761–769
   PubMedGoogle Scholar
• Singh AP, Bafna S, Chaudhary K, Venkatraman G, Smith L, Eudy JD, Johansson SL, et al. 2008. Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. Cancer Lett 259:28–38
   Google Scholar
• Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, et al. 2006. The consensus coding sequences of human breast and colorectal cancers. Science 314:268–274
   PubMed Web of Science ®Google Scholar
• Smith FM, Vearing C, Lackmann M, Treutlein H, Himanen J, Chen K, Saul A, et al. 2004a. Dissecting the EphA3/Ephrin-A5 interactions using a novel functional mutagenesis screen. J Biol Chem 279:9522–9531
   PubMedGoogle Scholar
• Smith LM, Walsh PT, Rudiger T, Cotter TG, McCarthy TV, Marx A, O'Connor R. 2004b. EphA3 is induced by CD28 and IGF-1 and regulates cell adhesion. Exp Cell Res 292:295–303
   PubMedGoogle Scholar
• Solanas G, Cortina C, Sevillano M, Batlle E. 2011. Cleavage of E-cadherin by ADAM10 mediates epithelial cell sorting downstream of EphB signalling. Nat Cell Biol 13:1100–1107
   PubMed Web of Science ®Google Scholar
• Soverini S, Colarossi S, Gnani A, Castagnetti F, Astolfi A, Formica S, Palandri F, et al. 2009. High-resolution molecular allelokaryotyping of chronic myeloid leukemia patients in blast crisis by 6.0 SNP-Arrays shows a high frequency of uniparental disomy and focal copy number alterations affecting the whole sequence or specific exons of oncogenes and tumor suppressor genes. Blood (ASH Annual Meeting Abstracts) 114:2176
   Google Scholar
• Stapleton D, Balan I, Pawson T, Sicheri F. 1999. The crystal structure of an Eph receptor SAM domain reveals a mechanism for modular dimerization. Nat Struct Biol 6:44–49
   PubMedGoogle Scholar
• Stein E, Huynh-Do U, Lane AA, Cerretti DP, Daniel TO. 1998a. Nck recruitment to Eph receptor, EphB1/ELK, couples ligand activation to c-Jun kinase. J Biol Chem 273:1303–1308
   PubMed Web of Science ®Google Scholar
• Stein E, Lane AA, Cerretti DP, Schoecklmann HO, Schroff AD, Van Etten RL, Daniel TO. 1998b. Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev 12:667–678
   PubMedGoogle Scholar
• Stephen LJ, Fawkes AL, Verhoeve A, Lemke G, Brown A. 2007. A critical role for the EphA3 receptor tyrosine kinase in heart development. Dev Biol 302:66–79
   PubMedGoogle Scholar
• Stubbs J, Palmer A, Vidovic M, Marotte LR. 2000. Graded expression of EphA3 in the retina and ephrin-A2 in the superior colliculus during initial development of coarse topography in the wallaby retinocollicular projection. Eur J Neurosci 12:3626–3636
   PubMedGoogle Scholar
• Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. 2000. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157:411–421
   PubMed Web of Science ®Google Scholar
• Ting MJ, Day BW, Spanevello MD, Boyd AW. 2010. Activation of ephrin A proteins influences hematopoietic stem cell adhesion and trafficking patterns. Exp Hematol 38:1087–1098
   PubMedGoogle Scholar
• To C, Farnsworth R, Vail M, Chheang C, Gargett C, Murone C, Llerena C, et al. 2014. Hypoxia-controlled EphA3 marks a human endometrium derived multipotent mesenchymal stromal cell that supports vascular growth. PLoS One (in press)
   Google Scholar
• Tognolini M, Hassan-Mohamed I, Giorgio C, Zanotti I, Lodola A. 2014. Therapeutic perspectives of Eph–ephrin system modulation. Drug Discov Today 19:661–669
   Google Scholar
• Tsai CC, Chen YJ, Yew TL, Chen LL, Wang JY, Chiu CH, Hung SC. 2011. Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. Blood 117:459–469
   PubMed Web of Science ®Google Scholar
• Tsai CC, Su PF, Huang YF, Yew TL, Hung SC. 2012. Oct4 and Nanog directly regulate Dnmt1 to maintain self-renewal and undifferentiated state in mesenchymal stem cells. Mol Cell 47:169–182
   PubMed Web of Science ®Google Scholar
• Vail ME, Murone C, Tan A, Hii L, Abebe D, Janes PW, Lee F-T, et al. 2014. Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment. Cancer Res 74:4470–4481
   PubMed Web of Science ®Google Scholar
• Valsesia A, Rimoldi D, Martinet D, Ibberson M, Benaglio P, Quadroni M, Waridel P, et al. 2011. Network-guided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma. PLoS ONE 6:e18369
   Google Scholar
• Vearing C, Lee FT, Wimmer-Kleikamp S, Spirkoska V, To C, Stylianou C, Spanevello M, et al. 2005. Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: Potential as EphA3-specific tumor-targeting reagents. Cancer Res 65:6745–6754
   PubMedGoogle Scholar
• Vecchi M, Confalonieri S, Nuciforo P, Vigano MA, Capra M, Bianchi M, Nicosia D, et al. 2008. Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene 27:2148–2158
   Google Scholar
• Vindis C, Teli T, Cerretti DP, Turner CE, Huynh-Do U. 2004. EphB1-mediated cell migration requires the phosphorylation of paxillin at Tyr-31/Tyr-118. J Biol Chem 279:27965–27970
   PubMedGoogle Scholar
• Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC, Fenwick K, et al. 2012. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood 120:1077–1086
   PubMed Web of Science ®Google Scholar
• Wang HU, Chen ZF, Anderson DJ. 1998. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93:741–753
   PubMed Web of Science ®Google Scholar
• Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, Wartman LD, et al. 2012. The origin and evolution of mutations in acute myeloid leukemia. Cell 150:264–278
   PubMed Web of Science ®Google Scholar
• Wiesner S, Wybenga-Groot LE, Warner N, Lin H, Pawson T, Forman-Kay JD, Sicheri F. 2006. A change in conformational dynamics underlies the activation of Eph receptor tyrosine kinases. Embo J 25:4686–4696
   PubMed Web of Science ®Google Scholar
• Wimmer-Kleikamp SH, Janes PW, Squire A, Bastiaens PI, Lackmann M. 2004. Recruitment of Eph receptors into signaling clusters does not require ephrin contact. J Cell Biol 164:661–666
   PubMedGoogle Scholar
• Wimmer-Kleikamp SH, Nievergall E, Gegenbauer K, Adikari S, Mansour M, Yeadon T, Boyd AW, et al. 2008. Elevated protein tyrosine phosphatase activity provokes Eph/ephrin-facilitated adhesion of pre-B leukemia cells. Blood 112:721–732
   PubMedGoogle Scholar
• Wood LD, Calhoun ES, Silliman N, Ptak J, Szabo S, Powell SM, Riggins GJ, et al. 2006. Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. Human Mutat 27:1060–1061
   PubMedGoogle Scholar
• Wu Q, Suo Z, Risberg B, Karlsson MG, Villman K, Nesland JM. 2004. Expression of Ephb2 and Ephb4 in breast carcinoma. Pathol Oncol Res 10:26–33
   PubMed Web of Science ®Google Scholar
• Wybenga-Groot LE, Baskin B, Ong SH, Tong J, Pawson T, Sicheri F. 2001. Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 106:745–757
   PubMed Web of Science ®Google Scholar
• Xi H-Q, Wu X-S, Wei B, Chen L. 2012. Aberrant expression of EphA3 in gastric carcinoma: Correlation with tumor angiogenesis and survival. J Gastroenterol 47:785–794
   Google Scholar
• Xi H-Q, Zhao P. 2011. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. J Clin Pathol 64:498–503
   Google Scholar
• Xu K, Tzvetkova-Robev D, Xu Y, Goldgur Y, Chan YP, Himanen JP, Nikolov DB. 2013. Insights into Eph receptor tyrosine kinase activation from crystal structures of the EphA4 ectodomain and its complex with ephrin-A5. Proc Natl Acad Sci USA 110:14634–14639
   Google Scholar
• Yuan W, Chen Z, Wu S, Ge J, Chang S, Wang X, Chen J. 2009. Expression of EphA2 and E-cadherin in gastric cancer: Correlated with tumor progression and lymphogenous metastasis. Pathol Oncol Res 15:473–478
   PubMed Web of Science ®Google Scholar
• Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. 2007. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 67:10123–10128
   PubMed Web of Science ®Google Scholar
• Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. 2001. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61:2301–2306
   PubMed Web of Science ®Google Scholar
• Zhao H, Huang D, Caflisch A. 2012. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics. Chem Med Chem 7:1983–1990
   Google Scholar
• Zhong TP, Childs S, Leu JP, Fishman MC. 2001. Gridlock signalling pathway fashions the first embryonic artery. Nature 414:216–220
   PubMed Web of Science ®Google Scholar
• Zhuang G, Hunter S, Hwang Y, Chen J. 2007. Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-kinase-dependent Rac1 activation. J Biol Chem 282:2683–2694
   PubMedGoogle Scholar
• Zhuang G, Song W, Amato K, Hwang Y, Lee K, Boothby M, Ye F, et al. 2012. Effects of cancer-associated EPHA3 mutations on lung cancer. J Natl Cancer Inst 104:1183–1198
   Google Scholar
• Ziebarth JD, Bhattacharya A, Cui Y. 2012. Integrative analysis of somatic mutations altering microRNA targeting in cancer genomes. PLoS ONE 7:e47137
   Google Scholar